RT Journal Article
SR Electronic
T1 β-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure
JF Heart
JO Heart
FD BMJ Publishing Group Ltd and British Cardiovascular Society
SP 209
OP 214
DO 10.1136/hrt.2010.207365
VO 97
IS 3
A1 Giuseppe Ambrosio
A1 Marcus D Flather
A1 Michael Böhm
A1 Alain Cohen-Solal
A1 Adriano Murrone
A1 Flavio Mascagni
A1 Giulio Spinucci
A1 Maria Giovanna Conti
A1 Dirk J van Veldhuisen
A1 Luigi Tavazzi
A1 Andrew J S Coats
YR 2011
UL http://heart.bmj.com/content/97/3/209.abstract
AB Objectives This subanalysis of the Study of the Effects of Nebivolol Intervention on Outcomes and Hospitalisation in Seniors with Heart Failure (SENIORS) investigates whether treatment with nebivolol, a β-blocker with nitric oxide-releasing properties, can provide additional benefits besides its effects on heart failure (HF), by reducing cardiac ischaemic events in patients with HF of ischaemic aetiology.Design A double-blind, randomised, placebo-controlled, multicentre trial of nebivolol in 2128 elderly patients.Patients and interventions For this analysis, data were extracted for 2128 elderly (≥70 years) HF patients in whom coronary artery disease (CAD) was the underlying aetiology (68.2%; 717 placebo-treated patients and 735 assigned to nebivolol).Main outcome measures The main endpoint was the composite of cardiac ischaemic events at 2 year follow-up: death/hospitalisation for myocardial infarction, unstable angina or sudden death, as originally identified in the case report form.Results At follow-up, nebivolol treatment was associated with a one-third reduction in the risk of ischaemic events, the composite endpoint occurring in 15.9% of placebo and 10.7% of nebivolol-treated patients (HR 0.68; 95% CI 0.51 to 0.90; p=0.008). This effect was independent of age, gender and ejection fraction. No difference in this composite endpoint was observed in the subgroup of patients of non-ischaemic aetiology.Conclusions Nebivolol was effective in reducing cardiac ischaemic events in patients with HF of ischaemic aetiology. The prevention of ischaemic events can be an additional beneficial effect of β-blockade in HF patients with underlying CAD.